Syndax Pharmaceuticals (Nasdaq: SNDX), a US-based clinical stage biopharmaceutical company that is developing an innovative pipeline of cancer therapies, announced on Monday that it will host an in-person investor event, along with a live webcast, on Monday, 11 December 2023, at 7:00 am PT / 10:00 am ET during the 65th American Society of Hematology (ASH) Annual Meeting in San Diego, California.
The event will include new data for both the axatilimab and revumenib programs, and members of the Syndax management team will be joined by the following key opinion leaders:
Daniel Wolff, MD, professor of Hematology, Department of Internal Medicine III of the University of Regensburg.
Eytan M. Stein, MD, chief, program for Drug Development in Leukemia, Department of Medicine, Memorial Sloan Kettering Cancer Center.
Ghayas C. Issa, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center.
Joshua F. Zeidner, MD, associate professor of Medicine, chief, Leukemia Research, University of North Carolina, Lineberger Comprehensive Cancer Center.
Neerav N. Shukla, MD, chief, Pediatric Translational Medicine Service, Memorial Sloan Kettering Cancer Center.
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration